blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3976593

EP3976593 - MACROCYCLIC LIPIDS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  03.05.2024
Database last updated on 24.08.2024
FormerExamination is in progress
Status updated on  30.06.2023
FormerRequest for examination was made
Status updated on  04.03.2022
FormerThe international publication has been made
Status updated on  05.12.2020
Formerunknown
Status updated on  04.08.2020
Most recent event   Tooltip03.05.2024Application deemed to be withdrawnpublished on 05.06.2024  [2024/23]
Applicant(s)For all designated states
Translate Bio, Inc.
200 West Street
Waltham, MA 02451 / US
[2022/25]
Former [2022/14]For all designated states
Translate Bio, Inc.
29 Hartwell Avenue
Lexington, MA 02421 / US
Inventor(s)01 / ZHANG, Yi
C/o Translate Bio, Inc. 29 Hartwell Avenue
Lexington, MA 02421 / US
02 / KARVE, Shrirang
C/o Translate Bio, Inc. 29 Hartwell Avenue
Lexington, MA 02421 / US
03 / DEROSA, Frank
C/o Translate Bio, Inc. 29 Hartwell Avenue
Lexington, MA 02421 / US
04 / HEARTLEIN, Michael
C/o Translate Bio, Inc. 29 Hartwell Avenue
Lexington, MA 02421 / US
 [2022/14]
Representative(s)Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
[N/P]
Former [2022/14]Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Application number, filing date20746395.129.05.2020
[2022/14]
WO2020US35275
Priority number, dateUS201962855256P31.05.2019         Original published format: US 201962855256 P
[2022/14]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020243540
Date:03.12.2020
Language:EN
[2020/49]
Type: A1 Application with search report 
No.:EP3976593
Date:06.04.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 03.12.2020 takes the place of the publication of the European patent application.
[2022/14]
Search report(s)International search report - published on:EP03.12.2020
ClassificationIPC:C07D321/00, C07D323/00, C07D405/06, C07D493/10, C07C219/06, A61P43/00, A61K48/00
[2022/14]
CPC:
C07D321/00 (EP,US); A61K9/1272 (US); A61K38/177 (US);
A61K38/45 (US); A61K39/385 (US); A61K48/0033 (US);
A61P43/00 (EP); C07C219/06 (EP); C07C229/12 (US);
C07D323/00 (EP); C07D405/06 (EP,US); C07D405/14 (US);
C07D493/10 (EP); C07D493/20 (US); A61K2039/53 (US);
A61K2039/6018 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/14]
TitleGerman:MAKROCYCLISCHE LIPIDE[2022/14]
English:MACROCYCLIC LIPIDS[2022/14]
French:LIPIDES MACROCYCLIQUES[2022/14]
Entry into regional phase14.12.2021National basic fee paid 
14.12.2021Designation fee(s) paid 
14.12.2021Examination fee paid 
Examination procedure14.12.2021Amendment by applicant (claims and/or description)
14.12.2021Examination requested  [2022/14]
14.12.2021Date on which the examining division has become responsible
03.07.2023Despatch of a communication from the examining division (Time limit: M06)
16.01.2024Application deemed to be withdrawn, date of legal effect  [2024/23]
06.02.2024Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2024/23]
Fees paidRenewal fee
31.03.2022Renewal fee patent year 03
14.03.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[AD]WO2010042877  (TEKMIRA PHARMACEUTICALS CORP [CA], et al) [AD] 6-28 * Title; abstract; claims; exaamples. *;
 [AD]WO2015184256  (SHIRE HUMAN GENETIC THERAPIES [US]) [AD] 6-28 * Title; abstract; claims; examples. *;
 [AD]WO2017117528  (ACUITAS THERAPEUTICS INC [CA]) [AD] 6-28* Title; abstract; claims, examples 3-6. *;
 [A]WO2017218524  (RANA THERAPEUTICS INC [US]) [A] 6-28 * Title; abstract; claims 1, 9-11. *
by applicantWO2013149140
 WO2012170889
 US4373071
 US4401796
 US4415732
 US4458066
 US4500707
 US4668777
 US4897355
 US4973679
 US5047524
 US5132418
 US5153319
 US5171678
 US5262530
 US5334761
 US5700642
 US5744335
 US5780014
 US5885613
 WO2005121348
 WO2010042877
 WO2010053572
 WO2010144740
 US8093367
 US8304529
 WO2013063468
 WO2015095340
 WO2015184256
 WO2015199952
 WO2016004202
 US2016031928
 WO2016118725
 WO2016118724
 WO2016205691
 WO2017004143
 WO2017049245
 WO2017075531
 WO2017117528
 WO2017173054
 WO2018089801
    - S. M. BERGE et al., "pharmaceutically acceptable salts in detail", J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19
    - JEMIELITY, J. et al., "Novel 'anti-reverse' cap analogs with superior translational properties", RNA, (20030000), vol. 9, doi:10.1261/rna.5430403, pages 1108 - 1122, XP002466761

DOI:   http://dx.doi.org/10.1261/rna.5430403
    - JEMIELITY, J. et al., RNA, (20030000), vol. 9, pages 1108 - 1122
    - GRUDZIEN, E. et al., RNA, (20040000), vol. 10, pages 1479 - 1487
    - GRUDZIEN-NOGALSKA, E. et al., RNA, (20070000), vol. 13, pages 1745 - 1755
    - YOKOE, Nature Biotechnology, (19960000), vol. 14, pages 1252 - 1256
    - GAO et al., Biochem. Biophys. Res. Comm., (19910000), vol. 179, page 280
    - LASIC, Trends Biotechnol., (19980000), vol. 16, pages 307 - 321
    - J. MCCLELLANM. C. KING, Cell, (20100000), vol. 141, pages 210 - 217
    - WHITEHEAD et al., Nature Communications, (20140000), vol. 5, page 4277
    - FEIGNER et al., Proc. Nat'l Acad. Sci., (19870000), vol. 84, page 7413
    - BEHR et al., Proc. Nat.'1 Acad. Sci., (19890000), vol. 86, page 6982
    - SEMPLE et al., Nature Biotech., (20100000), vol. 28, pages 172 - 176
    - HEYES, J. et al., J Controlled Release, (20050000), vol. 107, pages 276 - 287
    - MORRISSEY, DV. et al., Nat. Biotechnol., (20050000), vol. 23, no. 8, pages 1003 - 1007
    - WOLF et al., BioTechniques, (19970000), vol. 23, page 139
    - KLIBANOV et al., FEBS Letters, (19900000), vol. 268, no. 1, pages 235 - 237
    - LUBKE et al., "Proteomics of the Lysosome", Biochim Biophys Acta, (20090000), vol. 1793, doi:10.1016/j.bbamcr.2008.09.018, pages 625 - 635, XP026073291

DOI:   http://dx.doi.org/10.1016/j.bbamcr.2008.09.018
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.